Table 3 Correlative biomarkers in subjects treated with mTMZ. Tumor blood flow was measured by arterial spin labeling (ASL) MRI while CSF levels of aMMP-2, aMMP-9 and sIL-2α were measured by ELISA
From: Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
No | Number of ASL scans | Tumor blood flow | aMMP-2 | aMMP-9 | sIL-2Rα | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|  |  | Blood flow average (cc/g · min, across all time points) | Blood flow ratio (Baseline) | Blood flow ratio (Mean, across all time points) | Baseline (ng/mL) | Mean (ng/mL) | Baseline (pg/mL) | Mean (pg/mL) | Baseline (pg/mL) | Mean (pg/mL) |
1 | 2 | 11.7 | 0.98 | 1.08 | Â | Â | Â | Â | Â | Â |
2 | 2 | 42.4 | 0.99 | 0.99 | Â | Â | Â | Â | Â | Â |
3 | 2 | 26.0 | 1.35 | 1.31 | Â | Â | Â | Â | Â | Â |
4 | 2 | 21.8 | 0.80 | 0.64 | 13.7 | 7.0 | 13.2 | 11.0 | 0 | 0 |
5 | 5 | 23.4 | 0.70 | 0.88 | 13.9 | 13.4 | 5.7 | 7.2 | 11.3 | 9.7 |
6 | 18 | 42.2 | 0.92 | 0.90 | 16.7 | 16.7 | 6.6 | 7.3 | 19.5 | 18.1 |
7 | 2 | 46.3 | 0.68 | 0.88 | 9.7 | 12.5 | 5.9 | 9.2 | 0 | 3.8 |
8 | 9 | 17.1 | 0.59 | 0.58 | 13.9 | 15.1 | 11.9 | 8.4 | 18.1 | 21.9 |
9 | 7 | 13.8 | 0.91 | 0.58 | 14.0 | 11.2 | 4.0 | 3.8 | 0 | 2.5 |